The session on Relapsed MM, chaired by Dr. Kenneth Anderson, began with a presentation by Dr. Nizar Bahlis focusing on one of the most common clinical problems: the management of lenalidomide-refractory patients. Dr. Salomon Manier presented on challenges in the management of patients with late-stage disease, in which refractoriness to multiple drug classes is the major problem. Dr. Paula Rodriguez-Otero focused on the goals of treating RRMM and Dr. Ajay Nooka covered upcoming novel therapies.
These talks were followed by abstract presentations. Dr. Naresh Bumma presented data on the bispecific CD3xBCMA antibody REGN5458. Dr. Hang Quach spoke on belantamab in combination with carfilzomib and dexamethasone. Dr Kevin Reyes presented data on the salvage therapies after anti-BCMA CART, which is becoming of special interest as more patients are treated with cellular therapies. Other abstracts in different sessions also presented data in the efficacy of bi-specific antibodies or their combinations. The results of these studies emphasize the great progress that has been achieved in the management of relapse or refractory disease and the increasing options available either with single agent or combination therapies. Dr. Shaji Kumar presented results from the MyDRUG study which treated patients based on their genomic profile. Patients were treated with mutation-specific therapies and the results of targeting the RAS mutated subgroup, introducing “mutation-specific” therapy in myeloma as in solid tumors. New and existing data were then discussed in depth by Drs. Ruben Niesvisky, Dorotea Fantl, Pieter Sonneveld and Michele Cavo, framing the current and future environment for treatment for relapsed or refractory disease.
